All Oncology News

The OncLive® News page includes the latest in clinical oncology news, including breaking regulatory decisions, clinical trial findings, pivotal and practice-changing data published in academic peer-reviewed journals, and more across solid and hematologic malignancies. Regulatory news includes new drug approvals by the FDA and European Union, priority review and breakthrough therapy designations, and orphan drug and fast track statuses.

ALL Treatment Paradigm Displays Significant Gains as NCCN Guidelines Evolve

December 6th 2024

The therapeutic arsenal for patients with ALL in the first line and beyond is expanding beyond traditional approaches, enabling better outcomes for patients.

Immunotherapy Reshapes Perioperative Strategies for Early NSCLC Without Driver Mutations

December 5th 2024

Roy S. Herbst, MD, explores evolving chemoimmunotherapy strategies for early-stage NSCLC that does not harbor actionable mutations.

Preclinical Data Highlight YAP1 and KRAS as Drivers in Soft Tissue Sarcomas

December 5th 2024

R. Lor Randall, MD, FACS, discusses advancements in preclinical research identifying therapeutic vulnerabilities in soft tissue sarcomas.

Chemotherapy-Free Regimen Shows Promise in HER2+/HR+ Metastatic Breast Cancer

December 5th 2024

DETECT V trial data suggest dual HER2-targeted and endocrine therapy might be an effective option in HER2+/HR+ breast cancer.

Immunotherapy Redefines Standard of Care for Frontline Advanced Endometrial Cancer

December 5th 2024

Monica H. Vetter, MD, discusses the integration of immunotherapy into chemotherapy regimens for frontline advanced endometrial cancer.

FDA Grants Fast Track Designation to PT217 for Neuroendocrine Prostate Cancer

December 5th 2024

The FDA granted fast track designation to PT217 for the treatment of patients with metastatic de novo or treatment-emergent neuroendocrine prostate cancer.

FDA to Review sBLA for Glofitamab Plus Chemotherapy in Relapsed/Refractory DLBCL

December 5th 2024

A sBLA has been accepted for review seeking the approval of glofitamab plus gemcitabine and oxaliplatin for pretreated, transplant-ineligible patients with relapsed/refractory DLBCL.

FDA Grants Fast Track Designation to CRB-701 in Relapsed/Refractory Cervical Cancer

December 5th 2024

CRB-701 has received FDA fast track designation for the treatment of adult patients with relapsed/refractory metastatic cervical cancer.

Tomorrow’s Promise, Today’s Roswell Park: Leaders Tackling the Biggest Priorities in Cancer Care and Treatment

December 5th 2024

Roswell Park CEO Candace S. Johnson, PhD, introduces center’s first Physician in Chief, leaders in strategic areas

PYX-201 Generates Responses and Contributes to Growing ADC Use in Solid Tumors

December 5th 2024

Glenn J. Hanna, MD, discusses data with PYX-201, expanding on the phase 1 trial which evaluated the agent in head and neck squamous cell carcinoma.

FDA Approves Durvalumab for Limited-Stage Small Cell Lung Cancer

December 4th 2024

The FDA has approved durvalumab for adults with limited-stage small cell lung cancer whose disease has not progressed following concurrent platinum-based chemotherapy and radiation therapy.

Immune Profile Score Could Enhance Immunotherapy Decision-Making in Solid Tumors

December 4th 2024

Sandip P. Patel, MD, discusses the functionality of the IPS test and the potential role of IPS as a biomarker in clinical practice.

Toripalimab Plus Chemo Stands Alone as Preferred Frontline Regimen in Updated NCCN Guidelines for Advanced Nasopharyngeal Carcinoma

December 4th 2024

The NCCN has released updated guidelines for the management of nasopharyngeal carcinoma.

FDA Grants Accelerated Approval to Zenocutuzumab for NRG1+ NSCLC and Pancreatic Adenocarcinoma

December 4th 2024

The FDA granted accelerated approval to zenocutuzumab for select patients with NSCLC and pancreatic adenocarcinoma with NRG1 fusions.

NGS and Novel Therapies Lends to Prolonged Survival Outcomes in HR+/ HER2– Breast Cancer

December 4th 2024

Francisco J. Esteva, MD, PhD, discusses how NGS sequencing, PIK3CA-targeted therapies, and ADCs are reshaping treatment in HR+/HER2– breast cancer.

NICE Recommends Tebentafusp Reimbursement for HLA-A*02:01+ Uveal Melanoma

December 4th 2024

NICE has recommended the reimbursement for tebentafusp in HLA-A*02:01–positive unresectable or metastatic uveal melanoma.

TERN-701 Decreases BCR-ABL Levels, Generates Molecular Responses in R/R CML

December 4th 2024

TERN-701 reduced BCR-ABL levels and produced molecular responses in relapsed/refractory chronic myeloid leukemia.

Fox Chase Cancer Center’s Dr. Anthony M. Villano and Dr. Austin D. Williams Named Fellows of the American College of Surgeons

December 4th 2024

Fox Chase Cancer Center’s Anthony M. Villano, MD, FACS, and Austin D. Williams, MD, MSED, FACS, were named Fellows of the American College of Surgeons.

TRANSCEND CLL 004 Analysis Proposes Meaningful Change Thresholds for PRO Measures in R/R CLL

December 4th 2024

Meaningful thresholds for interpreting changes in 3 EORTC QLQ-CLL17 domain scores have been identified in a PRO analysis of the TRANSCEND CLL 004 trial.

Disitamab Vedotin Shows Early Efficacy in HER2-Expressing Breast Cancer With PAM Pathway Abnormalities

December 4th 2024

Disitamab vedotin showed early activity in HER2-expressing metastatic breast cancer with abnormal PAM pathway activation.